CD40 Agonistic Antibody APX005M in Combination With Nivolumab
Status:
Completed
Trial end date:
2020-11-16
Target enrollment:
Participant gender:
Summary
This study is a Phase 1-2 open-label dose escalation study of the immuno-activating
monoclonal antibody APX005M administered in combination with nivolumab to adult subjects with
non-small cell lung cancer or metastatic melanoma. The Phase 1 portion is intended to
establish the maximum tolerated dose and the recommended phase 2 dose of APX005M when
administered in combination with nivolumab. The Phase 2 portion of the study will evaluate
safety and efficacy of the combination.